Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera
- PMID: 31008168
- PMCID: PMC6453827
- DOI: 10.1016/j.jdcr.2019.02.006
Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera
Keywords: JAK inhibitor; JAK, Janus kinase; JAK-STAT, Janus kinase–signal transducer and activator of transcription; Janus kinase inhibitor; Janus kinase–signal transducer and activator of transcription; PV, polycythemia vera; ruxolitinib; sarcoidosis.
Figures
References
-
- Valeyre D., Prasse A., Nunes H., Uzunhan Y., Brillet P.Y., Müller-Quernheim J. Sarcoidosis. Lancet. 2014;383(9923):1155–1167. - PubMed
-
- James C., Ugo V., Le Couédic J.P. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–1148. - PubMed
-
- Lower E.E., Smith J.T., Martelo 0.J., Baughman R.P. The anemia of sarcoidosis. Sarcoidosis. 1988;5:51–55. - PubMed
Publication types
LinkOut - more resources
Full Text Sources